La Jolla Pharmaceutical Company – Product Pipeline Review

Global Markets Direct’s, ‘La Jolla Pharmaceutical Company – Product Pipeline Review – 2016’, provides an overview of the La Jolla Pharmaceutical Company’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by La Jolla Pharmaceutical Company, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of La Jolla Pharmaceutical Company

The report provides overview of La Jolla Pharmaceutical Company including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses La Jolla Pharmaceutical Company’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features La Jolla Pharmaceutical Company’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate La Jolla Pharmaceutical Company’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for La Jolla Pharmaceutical Company

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding La Jolla Pharmaceutical Company’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

La Jolla Pharmaceutical Company Snapshot 5

La Jolla Pharmaceutical Company Overview 5

Key Information 5

Key Facts 5

La Jolla Pharmaceutical Company - Research and Development Overview 6

Key Therapeutic Areas 6

La Jolla Pharmaceutical Company - Pipeline Review 9

Pipeline Products by Stage of Development 9

Pipeline Products - Monotherapy 10

La Jolla Pharmaceutical Company - Pipeline Products Glance 11

La Jolla Pharmaceutical Company - Late Stage Pipeline Products 11

Phase III Products/Combination Treatment Modalities 11

La Jolla Pharmaceutical Company - Clinical Stage Pipeline Products 12

Phase I Products/Combination Treatment Modalities 12

La Jolla Pharmaceutical Company - Early Stage Pipeline Products 13

Preclinical Products/Combination Treatment Modalities 13

Discovery Products/Combination Treatment Modalities 14

La Jolla Pharmaceutical Company - Unknown Stage Pipeline Products 15

Unknown Products/Combination Treatment Modalities 15

La Jolla Pharmaceutical Company - Drug Profiles 16

LJPC-501 16

Product Description 16

Mechanism of Action 16

R&D Progress 16

LJPC-401 17

Product Description 17

Mechanism of Action 17

R&D Progress 17

LJPC-0712 18

Product Description 18

Mechanism of Action 18

R&D Progress 18

LJPC-30Sa 19

Product Description 19

Mechanism of Action 19

R&D Progress 19

LJPC-30Sb 20

Product Description 20

Mechanism of Action 20

R&D Progress 20

LJPC-6417 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

Small Molecule 1 To Inhibit ALK2 for Fibrodysplasia Ossificans Progressiva 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

Small Molecule 2 To Inhibit ALK2 for Fibrodysplasia Ossificans Progressiva 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

Small Molecule to Inhibit BMP for Cardiovascular, CNS, Oncology and Musculoskeletal Disorders 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

Drugs for Undisclosed Indications 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

La Jolla Pharmaceutical Company - Pipeline Analysis 26

La Jolla Pharmaceutical Company - Pipeline Products by Target 26

La Jolla Pharmaceutical Company - Pipeline Products by Route of Administration 27

La Jolla Pharmaceutical Company - Pipeline Products by Molecule Type 28

La Jolla Pharmaceutical Company - Pipeline Products by Mechanism of Action 29

La Jolla Pharmaceutical Company - Recent Pipeline Updates 30

La Jolla Pharmaceutical Company - Dormant Projects 33

La Jolla Pharmaceutical Company - Discontinued Pipeline Products 34

Discontinued Pipeline Product Profiles 34

GCS-100 34

LJPC-1010 34

La Jolla Pharmaceutical Company - Company Statement 35

La Jolla Pharmaceutical Company - Locations And Subsidiaries 37

Head Office 37

Other Locations & Subsidiaries 37

Appendix 38

Methodology 38

Coverage 38

Secondary Research 38

Primary Research 38

Expert Panel Validation 38

Contact Us 38

Disclaimer 39

List of Tables

List of Tables

La Jolla Pharmaceutical Company, Key Information 5

La Jolla Pharmaceutical Company, Key Facts 5

La Jolla Pharmaceutical Company – Pipeline by Indication, 2016 7

La Jolla Pharmaceutical Company – Pipeline by Stage of Development, 2016 9

La Jolla Pharmaceutical Company – Monotherapy Products in Pipeline, 2016 10

La Jolla Pharmaceutical Company – Phase III, 2016 11

La Jolla Pharmaceutical Company – Phase I, 2016 12

La Jolla Pharmaceutical Company – Preclinical, 2016 13

La Jolla Pharmaceutical Company – Discovery, 2016 14

La Jolla Pharmaceutical Company – Unknown, 2016 15

La Jolla Pharmaceutical Company – Pipeline by Target, 2016 26

La Jolla Pharmaceutical Company – Pipeline by Route of Administration, 2016 27

La Jolla Pharmaceutical Company – Pipeline by Molecule Type, 2016 28

La Jolla Pharmaceutical Company – Pipeline Products by Mechanism of Action, 2016 29

La Jolla Pharmaceutical Company – Recent Pipeline Updates, 2016 30

La Jolla Pharmaceutical Company – Dormant Developmental Projects,2016 33

La Jolla Pharmaceutical Company – Discontinued Pipeline Products, 2016 34

La Jolla Pharmaceutical Company, Subsidiaries 37

List of Figures

List of Figures

La Jolla Pharmaceutical Company – Pipeline by Top 10 Indication, 2016 7

La Jolla Pharmaceutical Company – Pipeline by Stage of Development, 2016 9

La Jolla Pharmaceutical Company – Monotherapy Products in Pipeline, 2016 10

La Jolla Pharmaceutical Company – Pipeline by Target, 2016 26

La Jolla Pharmaceutical Company – Pipeline by Route of Administration, 2016 27

La Jolla Pharmaceutical Company – Pipeline by Molecule Type, 2016 28

La Jolla Pharmaceutical Company – Pipeline Products by Mechanism of Action, 2016 29

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports

Analytics by GoSquared